Could psychostimulant drug use among university students be related to ADHD symptoms? A preliminary study.

ADHD Cognitive enhancement Methylphenidate Psychostimulant Students

Journal

Psychiatry research
ISSN: 1872-7123
Titre abrégé: Psychiatry Res
Pays: Ireland
ID NLM: 7911385

Informations de publication

Date de publication:
25 Nov 2023
Historique:
received: 20 09 2023
revised: 20 11 2023
accepted: 24 11 2023
medline: 4 12 2023
pubmed: 4 12 2023
entrez: 3 12 2023
Statut: aheadofprint

Résumé

We aimed to explore if psychostimulant use among student could be linked to attention deficit-hyperactivity disorder (ADHD) symptoms using a self-administered questionnaire sent by email to French students in 2021. Participants were asked about their psychostimulant use and the presence of ADHD symptoms using the Wender Utah Rating Scale and the Adult Self-Report Scale. Among the 4431 respondents, the prevalence of psychostimulant use was concerning and significantly associated with ADHD symptoms. This association could be related to undiagnosed ADHD or to psychobehavioral impairments induced by psychostimulant use underlining the need of ADHD screening and targeted prevention measures.

Identifiants

DOI: 10.1016/j.psychres.2023.115630 PMID: 38043409
pubmed: 38043409
pii: S0165-1781(23)00580-2
doi: 10.1016/j.psychres.2023.115630
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115630

Informations de copyright

Copyright © 2023. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest OC: speaker or chairman at industry symposia (Janssen, Recordati, Indivior) The other authors have no competing interest to disclose.

Auteurs

Clément Caron (C)

Pharmacology Department, Psychiatry and Addiction Medicine Department, CHU Lille, Addictovigilance Center, Lille F-59000, France.

Thibaut Dondaine (T)

Lille Neuroscience and Cognition, Degenerative and Vascular Cognitive Disorders, Pharmacology Department, University of Lille, Inserm, CHU Lille, UMR-S1172, Lille F-59000, France.

Axel Bastien (A)

Psychiatry and Addiction Medicine Department, CHU Lille, Lille F-59000, France.

Nathalie Chérot (N)

University of Lille, CHU Lille, Institut Pasteur de Lille, EA 4483 - IMPECS - IMPact de l'Environnement Chimique sur la Santé humaine, Lille F-59000, France.

Sylvie Deheul (S)

Pharmacology Department, CHU Lille, Addictovigilance Center, France.

Sophie Gautier (S)

Lille Neuroscience and Cognition, Degenerative and Vascular Cognitive Disorders, Pharmacology Department, University of Lille, Inserm, CHU Lille, UMR-S1172, Lille F-59000, France.

Olivier Cottencin (O)

Department of Psychiatry and Addiction Medicine, Plasticity & SubjectivitY (PSY) team, Lille Neuroscience & Cognition Centre (LiNC), CHU Lille, INSERM U-1172, France.

Sophie Moreau-Crépeaux (S)

University of Lille, University Student Health Services, France.

Régis Bordet (R)

Lille Neuroscience and Cognition, Degenerative and Vascular Cognitive Disorders, Pharmacology Department, University of Lille, Inserm, CHU Lille, UMR-S1172, Lille F-59000, France.

Louise Carton (L)

Lille Neuroscience and Cognition, Degenerative and Vascular Cognitive Disorders, Pharmacology Department, University of Lille, Inserm, CHU Lille, UMR-S1172, Lille F-59000, France. Electronic address: louise.carton@univ-lille.fr.

Classifications MeSH